News >

Simon Says Immunotherapy Combo Regimens on Horizon in NSCLC

Danielle Bucco
Published: Monday, Dec 04, 2017

There is a second layer of EGFR mutations that are not the classic immune EGFR mutations, such as exon 19 deletions. We do not have good drugs for those—particularly EGFR duplications for which currently we are using afatinib (Gilotrif). For patients with EGFR insertions, we do not have good [agents]. Those patients would benefit from any available clinical trials. 

The last couple of years have significantly changed lung cancer treatment with the explosion of immunotherapy and targeted agents. What’s next?

There is room for significant optimism in the current lung cancer therapeutic landscape. Newer drugs are showing improvements to PFS over older, existing drugs, which is a dramatic improvement. We are now seeing PFS pushing 2 years, and overall survival is now pushing 3 to 5 years. The lung cancer landscape has dramatically changed over the last decade or so and we are still scratching the surface. There are new data to come and more studies to be conducted, which will increase our understanding to optimally treat patients with advanced NSCLC.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication